Propanc Biopharma Inc (PPCB) FinancialsPPCBFinancialPropanc Biopharma Inc

Evaluating the bottom line, Propanc Biopharma Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -138.20%, provide a clear picture of how effectively PPCB converts its operational activities into shareholder value.

In the context of the broader market, PPCB competes directly with industry leaders such as VIVS and ELAB. With a market capitalization of $3.08M, it holds a significant position in the sector. When comparing efficiency, PPCB's gross margin of N/A stands against VIVS's N/A and ELAB's 7.99%. Such benchmarking helps identify whether Propanc Biopharma Inc is trading at a premium or discount relative to its financial performance.

PPCB has shown a concerning financial performance with negative net income figures, including -6360336 USD in Q3 2026. The company has a negative price-to-earnings ratio of -0.276716 and a forward price-to-earnings ratio of 0, indicating uncertainty in future earnings.